4.05
Replimune Group Inc (REPL) 最新ニュース
Join the Replimune Group (REPL) Securities Fraud Lawsuit Investigation - Claim Depot
REPL Stock Plunges 54% in 3 Months After FDA Rejects Skin Cancer Drug - TradingView
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming DeadlinesREPL - PR Newswire
Investigation announced for Long-Term Investors in shares - openPR.com
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune - FinancialContent
Strategies to average down on Replimune Group Inc.Market Movers & Technical Buy Zone Confirmation - newser.com
Replimune’s SWOT analysis: biotech stock faces FDA hurdles amid sector optimism - Investing.com
REPL Deadline: REPL Investors with Losses in Excess of $100K Have Opportunity to Lead Replimune Group, Inc. Securities Lawsuit Filed by The Rosen Law Firm - Morningstar
REPLIMUNE FINAL DEADLINE ALERT: Bragar Eagel & Squire, P.C. - GlobeNewswire
Replimune Group, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before September 22, 2025 to Discuss Your RightsREPL - WV News
Tools to assess Replimune Group Inc.’s risk profilePortfolio Risk Summary & Weekly Breakout Watchlists - newser.com
2025-09-22 | Shareholders of Replimune Group, Inc. (REPL): Protect Your Rights Before September 22, 2025Contact Levi & Korsinsky | NDAQ:REPL | Press Release - Stockhouse
REPL Investors Have Opportunity to Lead Replimune Group, Inc. Se - GuruFocus
REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Fraud Lawsuit with the Schall Law Firm - MarketScreener
Join Class Action to Recover Losses from Replimune Group, Inc. (REPL)Contact Levi & Korsinsky Before September 22, 2025 - Barchart.com
REPL INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
REPL FINAL DEADLINE ALERT: Replimune (REPL) Shares Tank 45% - GlobeNewswire
REPL FINAL DEADLINE ALERT: Replimune (REPL) Shares Tank 45% After Company Says No Pathway Identified For Lead Drug RP1, Securities Class Action Pending - GlobeNewswire Inc.
Levi & Korsinsky Notifies Replimune Group, Inc. (REPL) InvestorsLead Plaintiff Deadline on September 22, 2025 - Stockhouse
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune - GlobeNewswire
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune - GlobeNewswire Inc.
REPL DEADLINE TOMORROW: ROSEN, SKILLED INVESTOR COUNSEL, - GlobeNewswire
2025-09-20 | REPL LAWSUIT ALERT: Levi & Korsinsky Notifies Replimune Group, Inc. InvestorsLead Plaintiff Deadline September 22, 2025 | NDAQ:REPL | Press Release - Stockhouse
REPL Deadline: Rosen Law Firm Encourages Replimune Group, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important September 22 Deadline in Securities Class Action First Filed by the Firm – REPL | FinancialContent - FinancialContent
Replimune (REPL) Shares Tank 45% After Company Says No Pathway Identified For Lead Drug RP1, Securities Class Action PendingHagens Berman - PR Newswire
Replimune: Further Uncertainty Of RP1 Warrants Move To 'Hold' Rating (NASDAQ:REPL) - Seeking Alpha
JPMorgan Chase & Co. Reiterates "Underweight" Rating for Replimune Group (NASDAQ:REPL) - MarketBeat
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune - Newsfile
Class Action Filed Against Replimune Group, Inc. (REPL) Seeking Recovery for Investors – Contact Levi & Korsinsky - GlobeNewswire
Analyzing recovery setups for Replimune Group Inc. investors2025 Technical Patterns & Precise Buy Zone Identification - newser.com
Class Action Filed Against Replimune Group, Inc. (REPL) Seeking Recovery for Investors – ... - Bluefield Daily Telegraph
Why Replimune Stock Was Tumbling Again Today - AOL.com
Replimune (REPL) Stock Dips Amid FDA Meeting and Analyst Downgrade - GuruFocus
Shareholders SueWallSt in New Class Action Against Replimune Group, Inc.Act Now - Nasdaq
Replimune (REPL) Faces Downgrade Amid Regulatory Uncertainty - GuruFocus
Replimune stock downgraded at J.P. Morgan (REPL:NASDAQ) - Seeking Alpha
Replimune Group (REPL) Nosedives 39% as FDA Approval for Melanoma Treatment ‘Uncertain’ - Insider Monkey
REPLIMUNE ALERT: Bragar Eagel & Squire, P.C. Reminds - GlobeNewswire
JP Morgan Downgrades Replimune Group (REPL) to Underweight | REP - GuruFocus
Replimune stock unchanged as H.C. Wainwright maintains Neutral rating - Investing.com
This United Parcel Service Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Friday - Benzinga
BREAKING: Replimune Shares Drop Over 40%; Investors Should - GlobeNewswire
Factset, Metlife, Replimune - TradingView
Replimune stock rating downgraded by JPMorgan on regulatory concerns - Investing.com
Goldman Sachs Group Inc. Acquires 119,145 Shares of Replimune Group, Inc. $REPL - MarketBeat
REPLIMUNE GROUP, INC. (NASDAQ: REPL) SHAREHOLDER ALERT - GlobeNewswire
Why Replimune Stock Plummeted by Almost 40% Today - MSN
Replimune (REPL) Faces Setback After FDA Meeting - GuruFocus
Faruqi & Faruqi Reminds Replimune Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 22, 2025REPL - PR Newswire
REPLIMUNE DEADLINE: ROSEN, THE FIRST FILING FIRM, Encourages Replimune Group, Inc. Investors to Secure Counsel Before Important September 22 Deadline in Securities Class Action First Filed by the FirmREPL - MarketScreener
Replimune Group, Inc. Investors: Please contact the Portnoy - GlobeNewswire
Shareholders that lost money on Replimune Group, Inc. - GlobeNewswire
Replimune stock plunges after FDA meeting fails to clear path forward - Investing.com Australia
Replimune Group Completes FDA Meeting on RP1 Application - TipRanks
Replimune Stock Plunged 42% Today – Here’s Why - Stocktwits
Melanoma drug developer stock crashes after report from FDA meeting - The Business Journals
大文字化:
|
ボリューム (24 時間):